A decades-old epilepsy pill may hold the key to fixing joints that millions of Americans thought were permanently worn out. Yale researchers say lacosamide, a drug approved years ago for seizures, eased pain and helped cartilage heal in osteoarthritis models, especially when injected straight into the joint.
Quick Take
- Yale scientists found the epilepsy drug lacosamide reduced pain and cartilage damage in preclinical osteoarthritis studies.
- A collagen-II hydrogel delivered the drug directly into the joint, outperforming daily pills.
- The drug targets a protein tied to both pain signals and cartilage breakdown.
- Researchers call it a possible disease-modifying treatment, not just a painkiller.
An Old Drug Finds a New Job in the Joint
Lacosamide has treated epilepsy patients for about twenty years. It calms overactive nerve signals by blocking sodium channels in the brain. Yale researchers wondered if the same channel-blocking trick could quiet pain signals in arthritic joints, too. Their study, published in the journal Bioactive Materials, tested that idea directly on damaged cartilage.
The results surprised even the research team. Lacosamide did not just numb pain. It appeared to block a protein involved in both pain signaling and cartilage destruction, nudging damaged joints back toward repair instead of further breakdown, according to the study summary.
Why Delivery Location Changed Everything
Giving the drug as a daily pill worked, but injecting it straight into the joint worked far better. Researchers built a hydrogel from collagen II, a protein already found in healthy cartilage, to carry the drug and release it slowly over time. One injection every four weeks outperformed a daily oral dose, the Yale team reported.
That local delivery approach matters because joint tissue does not get much blood flow. Pills travel through the whole body before reaching the knee, losing strength along the way. A gel sitting right inside the joint keeps the medicine concentrated where damage is happening, protecting cartilage and blocking pain signals at the source.
A Protein That Does Double Duty
At the center of this discovery sits a sodium channel called Nav1.7. Yale orthopaedic researchers say targeting this specific protein, paired with local lacosamide delivery, did more than numb pain in preclinical models. It appeared to protect cartilage and encourage the tissue to rebuild itself.
That dual action separates this research from typical arthritis treatments. Most current options, like over-the-counter pain relievers or steroid shots, calm symptoms without touching the underlying damage. A drug that tackles both pain and structural breakdown at once would mark a real shift in how doctors approach the disease, rather than just masking it.
Putting the Hype in Context
Osteoarthritis research has seen plenty of promising lab results before. Scientists have spent years hunting for a true disease-modifying treatment, one that actually slows or reverses joint damage instead of just dulling pain. Few repurposed drugs make it past the animal-model stage into approved human therapies, and the field remains crowded with candidates that never cross that finish line.
That history does not diminish what Yale found. It explains why researchers describe lacosamide as a promising candidate rather than a finished cure. The drug already carries Food and Drug Administration (FDA) approval for epilepsy, which could speed up testing for a new use, since its safety profile in humans is already well established.
What Comes Next for Patients and Doctors
Osteoarthritis affects tens of millions of Americans, wearing down knees, hips, and hands as cartilage thins with age and use. Current treatment options mostly manage pain until surgery becomes necessary. A therapy that slows or repairs that damage would change daily life for older adults who want to stay active without constant joint pain holding them back.
Researchers now face the task of moving from animal models toward human trials. The hydrogel delivery system still needs testing for long-term safety and effectiveness in people. But a drug already proven safe for human use, paired with a smart delivery method, gives this research a real shot at reaching patients faster than a brand-new compound would.
FDA-approved epilepsy drug lacosamide shows potential to help reverse osteoarthritis damage. Yale researchers found it may block a protein involved in pain signaling and cartilage destruction, nudging damaged joints toward repair in preclinical studies. https://t.co/wFvuzgVMDo pic.twitter.com/A0PgUBXlWb
— Drew Grimaldi (@Grimillionaire) October 8, 2026
For now, the findings offer something rare in arthritis research: a concrete, peer-reviewed signal that cartilage damage might not be a one-way street. That alone is worth watching closely as this work moves toward the next stage of testing.
Sources:
sciencedaily.com, medicine.yale.edu, ua.news, inc.com
